BPC-157 + TB-500 Research Overview
A review of published research on BPC-157 and TB-500 (Thymosin Beta-4 fragment), two peptides studied for tissue repair and recovery in preclinical models.
Last updated: January 30, 2026
Research Documentation, Not Dosing Guidance
This page documents what researchers have studied in scientific literature. The doses mentioned are those used in specific studies, not recommendations. This is not a protocol guide and should not be used as dosing advice.
Research Summary
BPC-157 and TB-500 are two peptides that have been studied separately in preclinical research for their potential effects on tissue repair. BPC-157 is a synthetic pentadecapeptide derived from human gastric juice protein, while TB-500 is a fragment of Thymosin Beta-4, a naturally occurring protein involved in cell migration and wound healing. Researchers have investigated these compounds for their individual mechanisms, though combined research remains limited to theoretical rationale rather than direct comparative studies.
Proposed Mechanism of Combination
Researchers theorize that BPC-157 and TB-500 may have complementary mechanisms. BPC-157 research suggests involvement in angiogenesis (blood vessel formation), nitric oxide system modulation, and growth factor receptor interactions. TB-500 research indicates effects on actin polymerization, cell migration, and anti-inflammatory pathways. The theoretical basis for combination is that different tissue repair pathways might be addressed simultaneously - BPC-157 potentially supporting vascular and tendon tissue while TB-500 may influence cellular migration and inflammatory response. However, no controlled studies have directly examined combined administration.
Why Researchers Study This Combination
The interest in combining BPC-157 and TB-500 stems from their distinct but potentially complementary mechanisms as observed in preclinical research:
BPC-157 Research Focus
Published studies on BPC-157 have examined:
- Angiogenesis: Multiple rodent studies have observed increased blood vessel formation in wound healing models
- Tendon and ligament repair: Animal models suggest effects on tendon-to-bone junction healing
- Gastrointestinal protection: The peptide originates from gastric secretory protein and has been studied in GI models
- Nitric oxide system: Researchers have proposed modulation of the NO pathway as a mechanism
TB-500 Research Focus
Research on thymosin beta-4 and its fragment TB-500 has examined:
- Cell migration: In vitro studies show enhanced keratinocyte and endothelial cell movement
- Actin dynamics: The peptide sequesters G-actin, potentially facilitating cell motility
- Anti-inflammatory effects: Animal models have shown reduced inflammatory markers
- Cardiac repair: Rodent studies have explored effects after myocardial injury
The Evidence Gap
It is important to note what the research does not establish:
| Limitation | Explanation |
|---|---|
| No combined trials | No published studies examine BPC-157 + TB-500 together |
| Limited human data | BPC-157 has minimal human trials; TB-500 has none specific to this fragment |
| Single research groups | Much BPC-157 research comes from one Croatian research team |
| Translation uncertainty | Animal model results may not apply to humans |
Individual Peptide Research Summaries
BPC-157 Studies
Most BPC-157 research has been conducted in animal models with doses typically ranging from 10 ng/kg to 200 mcg/kg depending on the study design and administration route. Key areas investigated include:
- Tendon healing - Rat models with various tendon injury types
- Gastric mucosa - Protection against NSAID-induced damage
- Muscle healing - Rodent models of muscle crush injury
- Nerve regeneration - Limited preclinical exploration
The one small human trial used oral doses of 0.2-2.0 mg daily for gastric ulcer healing, but data interpretation is limited.
Thymosin Beta-4 / TB-500 Studies
TB-500 is a synthetic fragment of thymosin beta-4. Most research has been conducted using the full thymosin beta-4 protein rather than the TB-500 fragment specifically. Study doses varied widely:
- Dermal wound healing - Topical application (5 mcg per wound)
- Cardiac studies - Systemic administration (150-450 mcg total in mice)
- Corneal healing - Eye drop formulations in clinical development (RGN-259)
Research Context and Limitations
What Studies Do NOT Provide
- Optimal dosing: Studies used different doses for different purposes
- Safety profiles: Long-term safety data is lacking
- Human translation: Most data is from rodent or in vitro models
- Combined protocols: No research on the combination exists
Regulatory and Quality Considerations
Both peptides remain unapproved for human use by the FDA, EMA, and other major regulatory bodies. Products sold through research chemical suppliers:
- Lack quality verification
- Have unknown purity levels
- May contain contaminants or degradation products
- Are not subject to pharmaceutical manufacturing standards
This page documents research findings from peer-reviewed literature. It is not a treatment guide. The doses mentioned are those used in specific studies for research purposes, not recommendations for human use.
Studies Referenced
Stable gastric pentadecapeptide BPC 157 and wound healing PMID: 30915550
Sikiric P, et al.
Researchers used doses of 10 mcg/kg and 10 ng/kg in rat models, administered intraperitoneally or locally
BPC-157 demonstrated effects on angiogenesis and tendon-to-bone healing in rodent models. The study characterized potential mechanisms involving nitric oxide system modulation.
BPC-157 promotes tendon-bone healing PMID: 24614294
Chang CH, et al.
Researchers administered 200 mcg/kg via local injection at injury site in rat rotator cuff models
In a rat model of rotator cuff injury, BPC-157 treatment was associated with improved histological scores for tendon-bone interface healing compared to control groups.
Effect of pentadecapeptide BPC 157 on gastric ulcer healing PMID: 7521621
Sikiric P, et al.
Human participants received oral BPC-157 at doses of 0.2-2.0 mg daily for 4 weeks
Early human trials examined oral BPC-157 for gastric ulcer healing. Limited patient numbers and study design constrain interpretation, but safety profile was acceptable in this context.
Thymosin beta-4 accelerates wound healing PMID: 10401867
Malinda KM, et al.
Topical application of 5 mcg per wound in rodent dermal wound models
Thymosin beta-4 (the parent compound of TB-500) accelerated wound healing in rodent models, with researchers observing increased keratinocyte migration and collagen deposition.
Thymosin beta-4 promotes angiogenesis and cardiomyocyte migration PMID: 15543145
Bock-Marquette I, et al.
150 mcg injected intracoronarily followed by 450 mcg intraperitoneally in murine models
In mouse models of myocardial infarction, thymosin beta-4 was associated with reduced myocardial cell death and improved cardiac function markers.
Molecular mechanisms of thymosin beta-4 wound healing PMID: 22156923
Goldstein AL, et al.
Cell culture concentrations ranging from 1-100 ng/mL
In vitro studies characterized thymosin beta-4's role in actin sequestration, cell migration promotion, and anti-inflammatory signaling pathways.
BPC-157 as a therapy for inflammatory bowel disease PMID: 32156553
Sikiric P, et al.
10 mcg/kg administered intraperitoneally in rodent colitis models
Animal models of inflammatory bowel disease showed reduced tissue damage scores with BPC-157 treatment, with proposed mechanisms involving cytoprotective and anti-inflammatory pathways.
Safety Considerations from Research
Neither BPC-157 nor TB-500 is approved by the FDA or other major regulatory bodies for human use. The safety profile in humans remains inadequately characterized. Animal studies have not revealed major toxicity, but long-term effects, drug interactions, and safety in various populations (pregnancy, cardiovascular conditions, cancer history) are unknown. Both compounds are banned by WADA in competitive sports. Products obtained from research chemical suppliers have variable quality, purity, and contamination risks.
Disclaimer: This information summarizes published research for educational purposes only. It does not constitute medical advice, treatment recommendations, or dosing guidance. The doses mentioned are those used in specific studies, not recommendations. Neither BPC-157 nor TB-500 is approved for human use. Always consult qualified healthcare providers for medical decisions.